Short chains of amino acids that act as signaling molecules — interacting with specific receptors to regulate metabolism, inflammation, tissue repair, and cellular function.
Peptides don't broadly block or stimulate pathways. They act more selectively — binding to specific receptors and influencing targeted physiologic responses.
Some peptide therapies offered at Renuvo are investigational and not FDA-approved. All protocols follow clinical screening, structured oversight, and individualized risk–benefit assessment.
Peptides do not function like traditional medications that broadly block or stimulate pathways. Instead, they act more selectively — binding to specific receptors and influencing targeted physiologic responses. In many ways, peptides work by mimicking or supporting signals the body already uses naturally.
Some peptide-based therapies are well established in medicine, including insulin and GLP-1–based medications. Others are still being studied. Renuvo approaches both categories with the same rigor: indication-based, closely monitored, and transparent about what is known and what is not.
The effects depend on the specific peptide, the dose, and the individual patient. Depending on the peptide, physiologic influence may include:
Certain peptides interact with metabolic pathways to influence appetite regulation, energy balance, and cellular fuel utilization.
Some peptides modulate pro-inflammatory and anti-inflammatory signaling, potentially supporting balance in acute and chronic inflammatory states.
Certain peptides are studied for their role in accelerating tissue repair, reducing recovery time, and supporting healing after injury or exertion.
At the cellular level, peptides may influence gene expression, receptor sensitivity, and intracellular signaling cascades in targeted tissue types.
At Renuvo, peptide therapy is approached in two clearly defined categories.
Understanding the difference is central to how we discuss options with each patient.
Certain peptide-based treatments are FDA-approved and used within standard medical care. These include well-studied molecules with established safety profiles, dosing protocols, and clinical indications.
Examples include insulin and GLP-1 receptor agonists — molecules with decades of clinical data and regulatory approval.
Other peptides are not FDA-approved and are considered investigational. When appropriate, these may be used within a structured and closely monitored framework that includes:
Renuvo focuses on a limited number of peptide categories based on available research, clinical rationale, and the needs of our patient population.
Peptides involved in metabolic signaling pathways, including those related to appetite regulation, energy balance, and glucose metabolism. This includes both established and investigational agents.
Peptides studied for their role in tissue repair, post-exertion recovery, and the modulation of inflammatory responses that affect healing timelines.
Peptides under investigation for supporting gastrointestinal lining function, mucosal repair, and inflammatory balance within the gut environment.
These are not generalized treatments. Selection is based on individual clinical context, goals, and appropriateness.
No peptide is prescribed without a clear clinical rationale. We evaluate whether a therapy is appropriate before recommending it.
Each protocol is assessed against available research. We are transparent about the strength of evidence — and its limitations.
Contraindications, drug interactions, and patient-specific risk factors are reviewed before any protocol begins.
All protocols include follow-up, monitoring, and adjustment as needed. Therapies are discontinued if they are no longer appropriate.
Depending on your clinical needs, peptide therapy may be combined with complementary modalities that support the physiologic environment — improving circulation, reducing inflammation, and creating better conditions for tissue response.
The body’s physiologic state matters. Before certain therapies, we may focus on reducing sympathetic activation and supporting circulation to create a more favorable internal environment for recovery and tissue response.
Supports circulation, reduces surface-level inflammation, and helps prepare tissue for treatment response.
Supports a shift from sympathetic (stress-driven) to parasympathetic nervous system activation before treatment begins.
A low-stimulation, purposefully designed space to support the body's natural recovery and receptivity.
This is supportive, not a guarantee of outcome. These preparatory steps are designed to optimize conditions — not to override the body's natural processes.
Peptide therapy is not risk-free. At Renuvo, we take a conservative and structured approach to every protocol — starting with thorough screening and continuing through each stage of treatment.
This is not appropriate for casual or unsupervised use. Peptide therapy at Renuvo is a clinical service, not a wellness product.
Stay updated with wellness tips, clinic updates, and Renuvo insights.
Copyright © 2026 All Rights Reserved.
